Jeito Capital
Paris-based life-sciences venture capital fund founded 2018 by Rafaele Tordjman MD PhD (ex-Sofinnova Managing Partner) and dedicated to financing breakthrough biopharma innovation for patient benefit across Europe and North America. Two funds: Jeito I closed EUR 534M July 2021 and Jeito II closed EUR 1.23bn April 2026 (largest-ever independent biopharma-focused European fund per FierceBiotech) for around EUR 1.73bn total AUM. Portfolio of 22 cos with three confirmed Trade Sale exits 2023-2024 (Neogene Therapeutics to AstraZeneca USD 320M total 2023 + HI-Bio to Biogen USD 1.8bn total July 2024 + EyeBio to Merck USD 3bn total late 2024) plus Odyssey Therapeutics NASDAQ IPO May 2026 (ODTX, USD 304M raised).
Key facts
Recent exits
Coverage notes
2 funds tracked, 24 portfolio companies (20 active · 4 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Jeito Capital has raised, with its portfolio companies. Hand-checked from public filings.
Jeito IIVC2026 · 0yr€1.0B9 active
Unrealized
9 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Adcendo | Biotech | Denmark | 2026 |
| Alveus Therapeutics | Biotech | US | 2026 |
| Augustine Therapeutics | Biotech | Belgium | 2025 |
| Aviceda Therapeutics | Biotech | US | 2024 |
| Azafaros | Biotech | Netherlands | 2025 |
| Callio Therapeutics | Biotech | US | 2025 |
| Odyssey Therapeutics | Biotech | US | 2025 |
| ReproNovo | Biotech | Switzerland | 2024 |
| XyloCor Therapeutics | Biotech | US | 2024 |
Jeito IVC2021 · 5yr€534M11 active · 4 realized
Unrealized
11 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Advesya | Biotech | Spain | 2022 |
| Alentis Therapeutics | Biotech | Switzerland | 2021 |
| CatalYm | Biotech | Germany | 2022 |
| CDR-Life | Biotech | Switzerland | 2022 |
| Corteria Pharmaceuticals | Biotech | France | 2023 |
| InnoSkel | Biotech | France | 2020 |
| NMD Pharma | Biotech | Denmark | 2022 |
| Noema Pharma | Biotech | Switzerland | 2023 |
| Pulmocide | Biotech | United Kingdom | 2021 |
| Quell Therapeutics | Biotech | United Kingdom | 2021 |
| SparingVision | Biotech | France | 2020 |
Realized
4 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| EyeBio | Biotech | US | 2022 | 2024 | Trade Sale | – | |
| HI-Bio | Biotech | US | 2021 | 2024 | Trade Sale | – | |
| Neogene Therapeutics | Biotech | Netherlands | 2020 | 2023 | Trade Sale | – | |
| Precirix | Biotech | Belgium | 2022 | 2026 | Liquidation | – | – |
Saved GPs appear in your watchlist, one click from your workspace.
About Jeito Capital
Jeito Capital is a French private equity firm with €534 million of assets under management as of December 2024, headquartered in Paris. Founded in 2018, the firm focuses on buyout and growth equity investments in European mid-cap businesses across healthcare, deploying capital from successive flagship funds with institutional limited partner support.
Investment thesis
Jeito Capital deploys buyout capital into European mid-cap and small-cap businesses across healthcare, targeting majority equity positions in profitable companies with clear value-creation runways. Investment focus emphasises operational improvement, selective bolt-on M&A acceleration and selective international expansion across France and selectively across Europe, with capital deployed from successive flagship funds backed by institutional limited partners.
Recent activity
Realised exits across the current platform vintages remain limited, with the portfolio in active deployment and value-creation phase. The platform tracks 2 fund vehicles, 19 active portfolio companies and 0 realised exits across the strategy's history. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
France·€196.0BFrance·€13.2BFrance·€6.7BFrance·€4.3BFrance·€4.0BFrance·€4.0BFrance·€3.0BFrance·€2.8BFrance·€2.6BFrance·€2.5BFrance·€2.1BFrance·€2.0B